Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Gains from Investment Securities (2018 - 2024)

Historic Gains from Investment Securities for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Q4 2024 value amounting to $564000.0.

  • Arcturus Therapeutics Holdings' Gains from Investment Securities fell 8825.49% to $564000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $3.3 million, marking a year-over-year decrease of 2325.58%. This contributed to the annual value of $8.1 million for FY2024, which is 135.02% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Gains from Investment Securities of $564000.0 as of Q4 2024, which was down 8825.49% from $2.7 million recorded in Q1 2024.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Gains from Investment Securities peaked at $30.7 million during Q2 2022, and registered a low of -$4.3 million during Q3 2021.
  • Its 5-year average for Gains from Investment Securities is $5.1 million, with a median of $1.3 million in 2020.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Gains from Investment Securities plummeted by 15308.64% in 2021, and later skyrocketed by 64501.99% in 2024.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Gains from Investment Securities (Quarter) stood at $21.2 million in 2020, then crashed by 71.37% to $6.1 million in 2021, then surged by 405.79% to $30.7 million in 2022, then crashed by 84.38% to $4.8 million in 2023, then plummeted by 88.25% to $564000.0 in 2024.
  • Its Gains from Investment Securities stands at $564000.0 for Q4 2024, versus $2.7 million for Q1 2024 and $4.8 million for Q4 2023.